Company type | Private |
---|---|
Industry | Pharmaceutical |
Founded | (1954 | )
Founder | Jacques Servier |
Headquarters | , |
Products | Pharmaceuticals |
Revenue | €4.2 billion (FY 2018) |
Number of employees | 22,000 |
Website | Official website |
Footnotes / references [1][2] |
Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).[3]
The consolidated turnover for the 2018 financial year was €4.2 billion.[4] Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company. It has branches in 149 countries, achieving 82% of its sales outside France.[5][6] The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 22,000 employees worldwide.[7] The company's production sites produced 853 million drug boxes in 2013.[5]
The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.[8] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[9]
In 2018, Servier finalized the acquisition of Shire’s oncology branch in Boston and named David K. Lee as CEO. The official opening of Servier's new U.S. headquarters took place in 2019.[4]
In 2009, Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[10][11] Further investigations found that many previous safety alerts on that drug had been either missed or covered up, possibly due to the improper influence of the company.[11]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search